Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of bone mineral density loss after allogeneic stem cell transplantation
ACTRN12607000596404Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Percent change in bone mineral density compared to baseline. Started Aug 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12607000596404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000596404.